<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274921</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8250</org_study_id>
    <secondary_id>University Hospital Toulouse</secondary_id>
    <nct_id>NCT03274921</nct_id>
  </id_info>
  <brief_title>Biomarkers of Cardiovascular Complications in Chronic Kidney Disease</brief_title>
  <acronym>BioClaCK</acronym>
  <official_title>Identification of BIOmarkers for Detection and Understanding of Cardiovascular Complications in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of new retention solutes associated with cardiovascular (CV) toxicity in&#xD;
      Chronic Kidney Disease (CKD) patients will help to better understand the pathophysiological&#xD;
      mechanisms at stake and to prevent CKD-associated mortality and morbidity. For a molecule to&#xD;
      be defined as a toxic retention solute, plasma accumulation in the course of CKD has to be&#xD;
      demonstrated but also proof needs to be made that plasma accumulation during CKD is indeed&#xD;
      associated with an increased risk of CV complications. Moreover, precise determination of the&#xD;
      plasma concentration has to be performed in order to later study in vitro and in vivo the&#xD;
      toxic mechanisms involved. Based on previous results of plasma proteome analysis using mass&#xD;
      spectrometry, a previous study has selected 10 promising protein candidates. These proteins&#xD;
      accumulated in the plasma of patients during CKD progression and are known to be associated&#xD;
      with CV events in non-CKD patients. The objective of the present study is now to 1) evaluate&#xD;
      the association of the plasma accumulation of the 10 retention solutes with CV complications&#xD;
      in CKD patients and 2) determine their plasma concentration using ELISA. One hundred and&#xD;
      seventy six patients with advanced CKD will be included and divided in 2 groups: 44 patients&#xD;
      with history of CV complications in the past 4 years and 132 patients free of any CV&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma accumulation of new retention solutes</measure>
    <time_frame>Day 0</time_frame>
    <description>evaluate the plasma accumulation of the 10 retention solutes using mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine their plasma concentration</measure>
    <time_frame>Day 0</time_frame>
    <description>determine their plasma concentration using ELISA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Chronic Renal Disease</condition>
  <arm_group>
    <arm_group_label>Cardiovascular complication</arm_group_label>
    <description>patients with history of CV complications in the past 4 years had biological determination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No cardiovascular complication</arm_group_label>
    <description>patients free of any CV complications had biological determination</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biological determination</intervention_name>
    <description>Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients</description>
    <arm_group_label>Cardiovascular complication</arm_group_label>
    <arm_group_label>No cardiovascular complication</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of patients consulting in University Hospital toulouse&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with stage 4 or 5 CKD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with stage 1, 2 or 3 CKD&#xD;
&#xD;
          -  patient with solid tumor&#xD;
&#xD;
          -  patient with malignant blood disease&#xD;
&#xD;
          -  patient with acute kidney disease in the past 3 months&#xD;
&#xD;
          -  patient with acute glomerulonephritis in the past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislas FAGUER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hosptial Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular complications</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

